ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 157

Agreement Between DAS28, ACR/EULAR, SDAI, CDAI and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care

Cecilie Heegaard Brahe1, Lene Terslev2, Simon Krabbe3, Mikkel Østergaard4, Henrik Rogind5, Hanne Jensen6, Annette Hansen7, Jesper Nørregaard8, Søren Jacobsen9, Karen Ellegaard10, Viktoria Fana1, Lars Juul7, Tuan K. Huynh8, Dorte V. Jensen7, Natalia Manilo6, Karsten Heller Asmussen6, Per Brown-Frandsen9, Søren Tobias Torp-Pedersen11, Niels Steen Krogh12 and Merete Lund Hetland2, 1Center for Rheumatology and Spine Diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 2Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 3Center for Rheumatology and Spine diseases, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 4Center for Rheumatology and Spine Diseases, Glostrup Hospital, Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 5Center for Rheumatology and Spine Diseases, Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 6Department of Rheumatology, Copenhagen University Hospital at Frederiksberg-Bispebjerg, Denmark, Frederiksberg, Denmark, 7Department of Rheumatology, Copenhagen University Hospital at Gentofte - Herlev, Denmark, Gentofte, Denmark, 8Department of Rheumatology, Copenhagen University Hospital at Nordsjælland, Denmark, Hillerød, Denmark, 9Center for Rheumatology and Spine Diseases, Rigshospitalet - Glostrup, University of Copenhagen, Denmark, Glostrup, Denmark, 10Department of rheumatology, Frederiksberg-Bispebjerg Hospital, The Parker Institute, Copenhagen, Denmark, 11Department of Radiology, Copenhagen University Hospital at Glostrup, Denmark, Glostrup, Denmark, 12ZiteLab ApS, Copenhagen, Denmark

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: remission, rheumatoid arthritis (RA) and ultrasound

  • Tweet
  • Email
  • Print
Session Information

Date: Sunday, November 8, 2015

Title: Imaging of Rheumatic Diseases Poster I: Ultrasound, Optical Imaging and Capillaroscopy

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Different remission criteria are available for patients with rheumatoid arthritis (RA). None of the criteria includes imaging remission, even though studies have shown that many RA patients in sustained clinical remission have synovitis detectable by ultrasound (US), i.e. grey scale synovial hypertrophy and/or Doppler signal in the synovium.

We aim to investigate the agreement between different clinical remission criteria and remission defined by US in patients with RA receiving biological therapy in routine care.

Methods: A total of 117 RA patients in sustained remission (i.e. DAS28 ≤2.6 for ≥ 1 year and no radiographic progression the last year) on biological therapy were recruited. All patients underwent US of 24 joints for grading of grey scale (GS) synovial hypertrophy (0-3) and synovial Colour Doppler activity (CD) (0-3). Imaging remission was defined in two ways: either GS=0 and CD=0 in all 24 joints, or GS≤1 and CD=0 in all 24 joints.

Results: Baseline characteristics are shown in table 1. At baseline patients received the following disease-modifying antirheumatic drugs (DMARDs): methotrexate (MTX; 72%), sulphasalazine (3%), azathioprine (2%), leflunomide (2%), no DMARDs (21%) and the following treatment with biological therapy: abatacept (2%), adalimumab (28%), certolizumab (3%), etanercept (28%), golimumab (3%), infliximab (27%), tocilizumab (9%).

For patients fulfilling DAS28 remission criteria, US defined remission was present in 9% (GS=0 and CD=0 in all 24 joints, termed “very strict” US remission) or 29% (GS ≤ 1 per joint and CD=0 in all 24 joints, termed “strict” US remission) and 24% had CD>1 in at least 1 joint (table 1). For patients fulfilling other criteria for clinical remission (CDAI, SDAI and ACR/EULAR remission), patients were in very strict US remission in 12%, 12% and 10%, respectively and in strict US remission in 28%, 29% and 20%, respectively. CD activity > 1 in at least 1 joint was present in 22%, 25% and 22% of patients, respectively. The anatomical distribution of the GS synovial hypertrophy was 31% in metacarpophalangeal joints, 27% in metatarsophalangeal joints, 19% in wrists, 10% in knees, 7% in elbows and 6 % in ankles. Thus, 33% of the total GS synovial hypertrophy was observed in the feet, which are not included in the DAS28 remission criteria.

There were no significant differences in US findings (GS or CD) between patients in remission vs patients not in remission, no matter which clinical remission criteria were used.

Conclusion:

Subclinical synovitis was frequently detected by US in RA patients treated with biological drugs in routine care showing poor agreement between the clinical remission criteria and US remission. Further studies are needed to evaluate the benefit of US remission as a goal for treat to target strategies on patient-reported outcomes and radiographic progression.

 


Disclosure: C. H. Brahe, None; L. Terslev, UCB, 8,Abbott Laboratories, 8,MSD, 8,Pfizer Inc, 8,Roche Pharmaceuticals, 8; S. Krabbe, None; M. Østergaard, Abbott Immunology Pharmaceuticals, 9,Pfizer Inc, 9,BMS, 9,UCB, 9,Merck Pharmaceuticals, 9,Janssen Pharmaceutica Product, L.P., 9,Roche Pharmaceuticals, 9; H. Rogind, None; H. Jensen, None; A. Hansen, None; J. Nørregaard, None; S. Jacobsen, None; K. Ellegaard, None; V. Fana, None; L. Juul, None; T. K. Huynh, None; D. V. Jensen, None; N. Manilo, None; K. H. Asmussen, Abbott Laboratories, 9,Merck Pharmaceuticals, 9,Pfizer Inc, 9,Novartis Pharmaceutical Corporation, 9,UCB, 9,Berlin Chemie, 9; P. Brown-Frandsen, None; S. T. Torp-Pedersen, None; N. Steen Krogh, None; M. Lund Hetland, None.

To cite this abstract in AMA style:

Brahe CH, Terslev L, Krabbe S, Østergaard M, Rogind H, Jensen H, Hansen A, Nørregaard J, Jacobsen S, Ellegaard K, Fana V, Juul L, Huynh TK, Jensen DV, Manilo N, Asmussen KH, Brown-Frandsen P, Torp-Pedersen ST, Steen Krogh N, Lund Hetland M. Agreement Between DAS28, ACR/EULAR, SDAI, CDAI and Ultrasound Remission in Patients with Rheumatoid Arthritis Receiving Biological Treatment in Routine Care [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/agreement-between-das28-acreular-sdai-cdai-and-ultrasound-remission-in-patients-with-rheumatoid-arthritis-receiving-biological-treatment-in-routine-care/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/agreement-between-das28-acreular-sdai-cdai-and-ultrasound-remission-in-patients-with-rheumatoid-arthritis-receiving-biological-treatment-in-routine-care/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology